We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
In a move that could boost generic firms’ bottom lines, one of the country’s largest pharmaceutical benefit managers (PBMs) is offering coupons to waive the copayment for a generic drug treatment.
Despite sweeping new patent rules implemented last year to better balance the competition between brand and generic drugmakers, generic firms say the brand firm practice of making deals with generic firms to market authorized generic products is a threat to the industry.
Democratic presidential nominee Sen. John Kerry (D-Mass.) outlined a plan for reducing the cost of prescription drugs that includes negotiating lower prices for federal and state governments and legalizing the importation of Rx drugs.
Generic drug dispensing rate discrepancies between retail and mail-order pharmacies disappear when therapeutic classes are accounted for, according to a new study that rebuts critics who allege mail pharmacies steer patients to higher priced brand products.
Wholesale prices for nearly 200 of the most common brand drugs used by seniors increased far faster than the rate of inflation for the first three months of 2004, according to a recent study by the AARP.
An analysis of 197 brand drugs showed average increases of 3.4 percent during that period, compared to a 1.2 percent rate of inflation, the AARP said.
The governor of Illinois has approved legislation eliminating the ability of a state pharmaceutical advisory panel to block FDA-approved generic drugs from being substituted for their brand counterparts.
Hospira, a maker of injectable drugs created last year from the hospital-products business of Abbott Laboratories, is the latest firm to join the Generic Pharmaceutical Association (GPhA), whose members increasingly make more than just generic products.
The National Institutes of Health (NIH) has denied a request by an advocacy group to break patents on Abbott Laboratories’ AIDS drug Norvir (ritonavir) and authorize generic competition.
In an environment of spiraling costs for drug development and an increasing number of new drug failures, Accentia BioPharmaceuticals believes it has a business model that will enhance its chances for success and become a blueprint that others will follow.
New York state’s attorney general has asked Johnson & Johnson (J&J) for documents pertaining to the marketing, off-label sales and clinical trials of five of its drug products, according to an Aug. 3 company regulatory filing.